- Home
- EML vs TARA Comparison
EML vs TARA Comparison
Compare EML & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- TARA
- Stock Information
- Founded
- EML 1858
- TARA N/A
- Country
- EML United States
- TARA United States
- Employees
- EML N/A
- TARA N/A
- Industry
- EML Industrial Machinery/Components
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- TARA Health Care
- Exchange
- EML Nasdaq
- TARA Nasdaq
- Market Cap
- EML 144.5M
- TARA 126.5M
- IPO Year
- EML N/A
- TARA N/A
- Fundamental
- Price
- EML $23.25
- TARA $3.33
- Analyst Decision
- EML
- TARA Strong Buy
- Analyst Count
- EML 0
- TARA 7
- Target Price
- EML N/A
- TARA $20.67
- AVG Volume (30 Days)
- EML 13.4K
- TARA 450.2K
- Earning Date
- EML 08-05-2025
- TARA 08-05-2025
- Dividend Yield
- EML 1.91%
- TARA N/A
- EPS Growth
- EML N/A
- TARA N/A
- EPS
- EML N/A
- TARA N/A
- Revenue
- EML $271,440,503.00
- TARA N/A
- Revenue This Year
- EML $1.56
- TARA N/A
- Revenue Next Year
- EML $7.00
- TARA N/A
- P/E Ratio
- EML $11.06
- TARA N/A
- Revenue Growth
- EML 8.15
- TARA N/A
- 52 Week Low
- EML $19.06
- TARA $1.60
- 52 Week High
- EML $35.03
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- EML 48.92
- TARA 55.94
- Support Level
- EML $23.21
- TARA $3.25
- Resistance Level
- EML $23.80
- TARA $3.23
- Average True Range (ATR)
- EML 0.56
- TARA 0.17
- MACD
- EML -0.07
- TARA 0.04
- Stochastic Oscillator
- EML 32.56
- TARA 81.25
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).